The clinical application value of TACE combined with SPVE in the treatment of two stage hepatectomy / 中国医师杂志

ABSTRACT

Objective To investigate the clinical application value of liver transarterial chemoembolization (TACE) combined with selective portal vein embolization (SPVE) in the treatment of two stage hepatectomy.Methods From January 2010 to December 2013,120 patients with liver tumors who were not suitable for one stage hepatectomy admitted to our department were enrolled in this study.Among them,60 (control group) received TACE therapy and 60 (observation group) accepted TACE combined with SPVE treatment.The liver function,liver volume change,the second stage resection,survival rate,complication and adverse reaction were compared between the two groups after treatment,and the application value of the therapy was analyzed.Results All the patients were successfully completed the treatment.The aspartate aminotransferase (AST),alanine aminotransferase (ALT),and total bilirubin (TB) of the two groups were all recovered to the pre-treatment level on the 7th day after treatment,and there was no statistical difference between the two groups (P ＞ 0.05).Except for the 6th months,the survival rates of the observation group in 12th months,18 months and 24 months were all higher than those in the control group.The liver volume of the control group and the observation group increased to varying degrees,and the tumor volume showed varying degrees of atrophy.The residual liver volume (RLV) of the observation group was (527.29 ±58.69) cm3,which was increased and higher than the control group before the treatment (P ＜ 0.05).The implementation rate of the second stage operation was also higher than that of the control group (P ＜ 0.05).There were no serious complications in the two groups,and there was no significant difference between the two groups about adverse reactions (P ＞ 0.05).Conclusions The treatment of TACE combined with SPVE can effectively control tumor growth,increase RLV,so as to improve the resection rate and survival rate of patients with primary hepatectomy who can not undergo primary resection.